Разработка кандидатной субстанции рекомбинантного белка CRM197-Reference-Cited by-同舟云学术

Разработка кандидатной субстанции рекомбинантного белка CRM197

Published:2016-02-20 Issue:1 Volume:15 Page:93-98
ISSN:2073-3046
Container-title:Epidemiology and Vaccine Prevention
language:
Short-container-title:Epidemiology and Vaccine Prevention

Author:

Bogomolova E. G.,Dobrovol'skaya O. A.,Mirovskaya A. A.,Al-Shehadat R. I.,Fedorova E. A.,Dukhovlinov I. V.,Simbirtsev A. S.

Abstract

CRM197 is a non-toxic mutant of diphtheria toxin having a single amino acid substitution of a glycine for a glutamic acid in position 52. Being naturally nontoxic, CRM197 is a promising adjuvant and ideal carrier protein for conjugate vaccines. Typically, production of diphtheria toxic and non-toxic mutants are carried out in Corynebacterium diphtheria. Production of recombinant CRM197 in Escherichia coli is advantageous. It is simple, cheap and permits production of the target protein in a short time using a non-pathogenic microorganism. In this study the pharmacology grade substance of recombinant protein CRM197 was developed based on chemical properties of the protein. The substance of recombinant protein CRM197 is characterized by presence of 0.054 ng/mcg of CRM197 E. coli host cell protein, 1.26 pg/mcg of CRM197 E.coli Host Cell DNA and less than 0,078 EU endotoxins per 1 mg of recombinant protein CRM197.

Publisher

LLC Numicom

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,Epidemiology

Reference10 articles.

1. Blanchard-Rohner G. The B-cell response to a primary and booster course of MenACWY-CRM₁₉₇ vaccine administered at 2, 4 and 12 months of age. Vaccine. 2013; 31 (20): 2441 – 2448.

2. Malito E. Structural basis for lack of toxicity of the diphtheria toxin mutant CRM197. Proc. Natl. Acad. Sci. U. S. A. 2012; 109 (14): 5229–5234.

3. Pollard A.J. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat. Rev. Immunol. 2009; 9 (3): 213–220.

4. Shinefield H.R. Postlicensure surveillance for Haemophilus influenzae type b invasive disease after use of Haemophilus influenzae type b oligosaccharide CRM197 conjugate vaccine in a large defined United States population: a four-year eight-month follow-up. Pediatr. Infect. Dis. J. 1995; 14 (11): 978 – 981.

5. Black S. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr. Infect. Dis. J. 2000; 19 (3): 187 – 195.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Peptides of yeast Saccharomyces cerevisiae activated by the malt sprout extract: Preparation, identification and bioactivity;Food Bioscience;2024-10

2. Preparation of Differentiated Recombinant Human β2-Microglobulin and Mouse β2-Microglobulin Proteins for its Detection in Class I HLA Chimeric Molecules;Journal Biomed;2024-07-23